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Objective: Side effects of the most commonly used primary antituberculosis
(anti-TB) drugs may be mild as well as fatal. The aim of this study was to evaluate
the side effects of and the risk factors for developing side effects against anti-TB
drugs.
Patients and methods: Records of 1149 patients with established tuberculosis who
initially received anti-TB therapy were evaluated retrospectively. The major side
effects, which resulted in a definitive termination from 1 or more drugs related to
anti-TB therapy, and the risk factors associated with these side effects, were
analyzed.
Results: Ninety-five patients (8.3%), constituting 104 cases in total, experienced
side effects. Although the frequency of drug reactions were increased from 0.6% at
ages o20 to 5.2% at ages 20–40, no gender or age differences were observed
between patients who did and did not have side effects. While asymptomatic liver
function disturbance was established in 56 of the patients (4.9%) with initiation
of anti-TB therapy, the rate of hepatotoxicity was found to be 2.4% in this
present study. No age or gender differences were observed among those who
had hepatotoxicity and who had not. The major side effects were ototoxicity
(1.7%), hepatotoxicity (0.8%), neuropsychiatric manifestations (0.7%), and
hyperuricemia (0.6%).
Conclusions: It must be remembered that severe side effects associated with anti-
TB drugs were encountered with different frequencies especially among patientsElsevier Ltd. All rights reserved.
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Side effects of primary anti-TB drugs in TB 1835hospitalized for pulmonary tuberculosis, and these patients should be followed up by
closer monitoring for side effects related to anti-TB drugs.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Incidence of active pulmonary tuberculosis is
estimated to as high as 8 million new cases per
year worldwide as well as approximately 2 million
deaths per year. More than one-third of the world’s
population is infected with Mycobacterium tuber-
culosis. In addition, developed countries are
experiencing a resurgence of tuberculosis, whereas
tuberculosis has been a major challenge for health
care providers in developing countries for a long
time. There are several chemotherapeutic agents
that exist to treat mycobacterial infections. How-
ever, the necessity of utilization of multidrug
regimens has been associated with increased
incidence of side effects. These side effects may
be mild as well as fatal. A severe side effect against
1 of the primary antituberculosis (anti-TB) drugs,
which leads to the discontinuation of that drug, has
several complications including an increased mor-
bidity and mortality. At the same time, use of
alternative agents may result in greater problems
of toxicity and compliance. As a result, the risk of
treatment failure and relapses are higher.1–4 There-
fore monitoring is crucial, but costly. Awareness of
the risk groups may decrease the cost as well as the
incidence of serious drug-related adverse effects.
In this study, we aimed to determine the current
incidence of side effects and the risk factors
related to anti-TB drugs for side effects, with a
large number of hospital-admitted tuberculosis
patients over a time period of 15 years.Material and methods
Records of patients with active tuberculosis who
were admitted to the Respiratory Ward of a
University Clinic between 1984 and 2001 were
analyzed retrospectively.
Demographical features, radiological extension
of the disease, treatment modalities, history of
diabetes mellitus (DM), hepatitis, chronic renal
failure and history of alcohol consumption, in
addition to states of pregnancy or postpartum were
recorded.
The diagnosis was made either histologically or
microbiologically, or improvements in the clinicalstatus of the patients after completing a full course
of multidrug treatment for tuberculosis as evalu-
ated by their physician were also noted.
Radiological extension was defined as described
elsewhere: The disease was considered extensive if
cavities totaled X15 cm in diameter and/or mod-
erately dense infiltrates involved X75% of lung
fields on chest X-ray.5
Treatment was planned as recommended by our
national tuberculosis program; total treatment
period was 9 months. Patients first received
primary anti-TB drugs including a combination of
3 or 4 drugs [Isoniazid (INH), Rifampin (RIF),
Pyrazinamide (PZA), Ethambutol (EMB), or Strepto-
mycin (SM)] during an initial phase of 2 months,
followed by a continuation phase of 7 months
consisting of INH and RIF. Treatment was given
daily, and at least the initial phase administered
during hospitalization. Drug dosages are presented
in Table 1.
The side effects were recorded in the files of the
patients. Basal levels of transaminases and bilirubin
and a complete blood count were ordered for all
tuberculosis patients prior to the onset of the anti-
TB chemotherapy in our hospital. Regular labora-
tory monitoring including serum transaminases and
bilirubin levels was performed in hospitalized
patients. As part of our clinical practice, serum
transaminases and bilirubin levels were measured
twice a week in the first 2 weeks, weekly in the
following 2 weeks and 2 times during the second
month of initial therapy unless no findings or
symptoms of hepatitis were observed in the
hospital. All side effects were observed during the
hospital-stay of the patients including the first 6–8
weeks of the anti-TB chemotherapy. A major side
effect was defined as any adverse reaction that led
to the discontinuation of 1 or more drugs included
in the standard therapy.
An elevation in liver function tests, which do not
require drug cessation, is defined as ‘‘functional
liver disturbance’’. While receiving anti-TB treat-
ment, an increase in AST and/or ALT of more than 3
times the upper normal limit in the presence of
symptoms such as anorexia, nausea, vomiting or
abdominal pain, or in transaminases of more than 5
times the upper normal limit without symptoms,
and/or in total bilirubin to42mg/dl was accepted
as ‘‘hepatotoxicity’’.1 Definitive termination of 1 of
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Table 1 Characteristics of patients treated for active tuberculosis between years 1984 and 2001.
Age (years) n (%)
Mean (range) 36.1(13–92)
o20 84 (7.3)
20–40 686 (59.7)
40–60 270 (23.5)
460 109 (9.5)
Sex
Male 876 (76.2)
Female 273 (23.8)
Method of detection
Microbiological or histological 1092 (95)
Clinical diagnosis 57 (5)
Site of disease
Pulmonary TB (11 miliary) 1080 (93.9)
Pleural TB 52 (4.5)
Larynx TB 9 (0.8)
Lymph node TB 8 (0.7)
Drugs
Isoniazid 5mg/kg per day (max 300mg/day)
Rifampicin 10mg/kg per day (max 600mg/day, weighto50 kg; not exceed 450mg per day)
Pyrazinamide 25mg/kg per day (max; 2 g/day)
Ethambutol 15mg/kg per day (max; 1500mg/day)
Streptomycin 15mg/kg per day (max: 1 g/day, X60 year max; 750mg/day)
Comorbid conditions
Diabetes mellitus 82 (7.1)
COPD 23 (2)
Cor pulmonale 8 (0.7)
Chronic renal failure 8 (0.7)
HBsAg (+) 4 (0.3)
Epilepsy 5 (0.4)
History of alcohol consumption 3 (0.3)
Presence of malignant tumor 13 (1.1)
Presence of extensive disease 552 (48)
B.E. Gu¨lbay et al.18363 standard drugs related to therapy was considered
as ‘‘severe hepatotoxicity’’. Risk factors for hepa-
totoxicity such as gender, age, hepatitis, alcohol
consumption, and presence of additional disease
were also analyzed.
While receiving anti-TB treatment, an increase in
uric acid levels of more than 8mg/dl was accepted
as ‘‘hyperuricemia’’ that is a well-known side
effect of PZA.6 Patients with hyperuricemia and/
or arthralgia related to therapy were analyzed for
renal disease, concomitant use of loop-inhibiting
diuretics. Persistent hyperuricemia despite ade-
quate hydration, appropriate diet, and use of non-
steroidal anti-inflammatory agents, and/or arthral-
gia leading to being handicapped were accepted as
valid causes for quitting administration of the
drug.1
The number of patients with ‘‘ototoxicity’’
including auditory (e.g., tinnitus and high-fre-quency hearing loss) and vestibular (e.g., vertigo,
ataxia, and loss of balance) damages related
to SM was recorded.1 Patients’ files were searched
for the day of ototoxicity and modification related
to this side effect. The relationship between
the development of ototoxicity and risk factors
such as age, concomitant diseases or use of drugs
such as loop-inhibiting diuretics were also
searched.
INH-related neuropsychiatric manifestations in-
cluding psychosis, obsessive–compulsive neurosis,
dysphoria, memory loss, and inability to concen-
trate were recorded.1 The risk factors for psychia-
tric changes such as diabetes, old age, alcohol
consumption, hepatic or renal insufficiency were
also analyzed in these patients.
Cutaneous reactions such as pruritus with or
without rash and transient morbilliform rash were
recorded during the therapy.1
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Table 2 Any side effect occurred during anti-TB
treatment.
Side effect n patients (%)
Side effects of primary anti-TB drugs in TB 1837All other types of side effects such as flu-like
syndrome and retrobulbar neuritis causing loss of
visual activity and red–green color discrimination
related to EMB had been recorded by physicians.Total patients 95 (8.3)
Total events 104 (9.0)
Hepatotoxicity
Functional liver disturbance 56 (4.9)
Hepatotoxicity 28 (2.4)
Severe hepatotoxicity 9 (0.8)
Hyperuricemia (7arthralgia) 31 (2.6)
Ototoxicity 19 (1.7)
Psychiatric changes 8 (0.7)
Cutaneous reactions 7 (0.6)Statistics
All statistical analyses were performed using the
SPSS 11.0 statistical program (SPSS Inc., Chicago,
IL, USA). Values are expressed as medians with 95%
CI unless otherwise indicated. A P-value of less than
0.05 was considered significant. w2 and Fisher’s
exact test were utilized in the analysis of data.Flu-like syndrome 3 (0.3)
Gluteal abscess 2 (0.2)
Fever 2 (0.2)
Peripheral neuropathy 1 (0.1)
Changes in visual acuity 1 (0.1)
Hemolytic reaction 1 (0.1)
Change in glucose tolerance 1 (0.1)
Severe side effects 51 (4.4)
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Figure 1 The distribution of the patient’s number with
side effects positive according to age groups.Results
Among the 1149 patients that were evaluated, 876
(76.2%) were male. Characteristics of patients
treated for active tuberculosis are shown in Table 1.
All patients included in this study were Caucasian.
Patients with 20–40 years of age accounted for
59.7% of the total. We ensured that the doses
recommended by World Health Organization (WHO)
for anti-TB drugs were used in all patients.
Eleven patients died during treatment. However,
none of the deaths were attributed to side effects
of anti-TB drugs. They were ascribed to respiratory
failure and cor pulmonale (4 patients), metastatic
lung cancer (3 patients), coronary artery disease
(2 patients), massive hemoptysis (1 patient) and
acute renal insufficiency (1 patient).
Ninety-five patients (8.3%) had side effects, 9 of
which experienced a second adverse reaction. All
side effects observed during anti-TB treatment are
shown in Table 2. Although the frequency of drug
reactions were increased from 0.6% at ageso20 to
5.2% at ages 20–40, no gender or age differences
were observed among those who did and did
not have side effects (P ¼ 0:450 and 0.425,
respectively) (Fig. 1).
Hepatotoxicity
It is well known that INH, RIF, and PZA are the most
common potential drugs that cause hepatic injury.
In our study, among 84 patients who had increased
in liver function tests only 28 eventually experi-
enced hepatotoxicity urging the cessation of the
treatment. Severe hepatotoxicity leading to final
termination of at least 1 of the 3 standard drugs
was observed in 9 patients (0.8%).
Hepatotoxicity occurred in 28 patients (2.4%)
during anti-TB treatment, representing 2.5% of allfemale patients, and 2.3% of all male patients. Of
these, all had normal pretreatment liver transami-
nase levels. Although there was no statistically
significant difference in gender in those patients
who developed hepatotoxicity compared with who
those who did not (OR 1.071; 95%CI, 0.450–2.548;
P ¼ 0:876), it was shown that male gender implied
1.07-fold more risks for developing hepatotoxicity.
The mean age was 36.8717.2 years (16–80 years,
95% CI 30.1–43.4 years) in patients with hepato-
toxicity. No age difference was observed among
those who had hepatotoxicity and who had not (OR
1.003; 95%CI, 0.978–1.028; P ¼ 0:814). None had a
history of alcohol use and none were pregnant or
postpartum. Radiological extension did not show
any impacts of hepatotoxicity (OR 0.807; 95% CI
0.378–1.721; P ¼ 0:579). The odds ratio was 0.476
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P ¼ 0:468). Only 1 patient with HBsAg positivity
had hepatotoxicity.
Median days for evolving hepatotoxicity were
1577.1 days (95% CI 13.3–18.8 days). Liver function
tests returned normal in all patients when medica-
tions were discontinued. After laboratory findings
had returned to normal levels, the same drug
regimens with the same doses were restarted in 18
patients, while challenge dosages of the original
anti-TB drugs were added into the treatment regi-
men gradually, in the order: INH, RIF and PZA in 10
patients with daily monitoring of the patient’s
clinical condition and liver function. Median interval
between detection of hepatotoxicity and restart to
the therapy was 14.577.7 days (7–38 days, 95% CI
11.5–17.4 days). However, 11 patients had a second
hepatotoxicity with retreatment, but the treatment
regimens of only 9 patients had to be modified
according to relapsed hepatotoxicity.
Severe hepatotoxicity was noted in 5 patients
(27.8%), who were re-administered anti-TB treat-
ment with the same drug regimen and same doses
after hepatotoxicity. In patient group with anti-TB
drugs added into the treatment gradually, severe
hepatotoxicity was observed in 4 patients (40%).
Although rate of occurrence of severe hepatotoxi-
city in the re-treatment of tuberculosis was in higher
in the gradual reintroduction group (OR 1.73, 95% CI;
0.339–8.867), there was no distinction between
different re-treatment protocols and the risk of
developing severe hepatotoxicity (P ¼ 0:677).
Severe hepatotoxicity was observed in 9 pa-
tients. The most common drug, which had to be
terminated due to hepatotoxicity, was PZA. PZA
was ceased in 7 patients, whereas RIF was stopped
in only 2 patients. Severe hepatotoxicity was more
frequent among younger patients (P ¼ 0:038).
While we determined that all patients with severe
hepatotoxicity were in the 20–40 years age group,
severe hepatotoxicity was not observed among
patients o20 years. Although there was no statis-
tically significant difference between severe hepa-
totoxicity and gender (OR 2.5; 95% CI 0.312–20.1;
P ¼ 0:695), we determined that male gender
was associated with increased risk of severe
hepatotoxicity.Ototoxicity
Ototoxicity, the most important adverse reaction
caused by SM, was the main severe side effect
observed in this present study. While ototoxicity
was observed in 19 patients (%1.7) (mean age:
27.176.9 years; male/female: 15/4), the realincidence of ototoxicity was 3.2% in the patients
group who received SM (19/578). Ototoxicity
appeared on 2578.1 day of treatment (14–46 days,
95% CI 22.7–30.4 days). Tinnitus (in 9 patients),
dizziness/vertigo (in 5 patients), loss of balance (in
3 patients) and hearing disturbance (in 2 patients)
were recorded in the ototoxicity group. All patients
with ototoxicity had received an anti-TB treatment
including SM. In all patients, SM was discontinued
immediately after ototoxicity had been discovered.
Besides, none of these patients had a history of
renal insufficiency.
Ototoxicity was noted to be more common
among patients aged between 20 and 39 years.
There was no significant distinction between
ototoxicity and gender (OR 1.172; 95% CI 0.386–
3.560; P ¼ 0:780).Hyperuricemia
It is well known that anti-TB therapy with PZA may
affect the uric acid levels and lead to polyarthral-
gia. In our study, uric acid levels higher than 8mg/
dl were observed in 31 patients (2.7%). During anti-
TB treatment, termination of PZA due to hyperur-
icemia had become necessary in 7 patients (0.6%).
Arthralgia not responding to non-steroidal anti-
inflammatory drugs (NSAID) was accompanied with
hyperuricemia in 4 of the cases (0.3%). Median days
for developing hyperuricemia were 17.6 days (5–30
days, 95% CI 15.7–19.6 days).
There were no significant differences in age
(P ¼ 0:233) or gender (OR 0.765; 95% CI 0.311–
1.884; P ¼ 0:672) in those patients who developed
hyperuricemia compared with those who did not.
None of these patients had history of diuretic
usage.Psychiatric changes
We observed neuropsychiatric manifestations such
as psychosis (n ¼ 3), anxiety damage (n ¼ 2),
crying attack (n ¼ 1), behavioral change (n ¼ 1),
and suicidal tendency (n ¼ 1) related to INH in 8
patients (mean age: 35.8713.3 years; male/
female: 7/1). These side effects occurred on the
35.8713.3 days of the anti-TB treatment (17–60
days, 95% CI 24.7–44.0 days). No gender (OR 0.456;
95% CI 0.056–3.726; P ¼ 0:688) or age (P ¼ 0:841)
differences were observed among patients who had
and had not neuropsychiatric problems related to
INH. None of these patients had any previous
history of seizures. In addition, no risk factors
could be identified for the termination of
drug therapy due to psychiatric changes such as
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insufficiency.
Severe side effects
Fifty-one patients (4.4%) had severe side effects,
and 6 patients experienced a second major adverse
reaction, constituting a total of 57 (4.9%) events,
leading to final termination of 1 of the standard
drugs.
The major severe side effects were ototoxicity
(1.7%), hepatotoxicity (0.8%), neuropsychiatric
manifestations (0.7%), and hyperuricemia (0.6%).
The frequency of severe side effects was highest
for SM (1.9%), followed by PZA (1.5%) and INH
(0.8%) (Table 3). The median period of time
between the onset of therapy and detection of
severe side effect was 25.3711.2 days (7–55 days,
95% CI, 22.1–28.5 days).
Although all severe side effects were more
frequent among male patients, no statistically
significant differences were seen between male
and female patients for severe adverse effects (OR
1.47; 95% CI, 0.710–3.075; P ¼ 0:399). Patients in
the severe side effects group were significantly
younger than those in the non-severe side effects
group. There was a statistically significant distinc-
tion in age of those patients who had severe
adverse effect compared with those who had not
(P ¼ 0:035).
Other side effects
While cutaneous lesions were observed in 7
patients (0.6%) during the anti-TB treatment, aTable 3 Number of severe side effects due to INH, RIF,
Side effects INH n (%) RIF n (%)
Hepatotoxicity — 2 (0.2)
Ototoxicity — —
Psychiatric changes 8 (0.7) —
Hyperuricemia — —
Cutaneous reactions — 1 (0.1)
Fever — —
Flu-like syndrome — 3 (0.26)
Peripheral neuropathy 1 (0.1) —
Gluteal abscess — —
Hemolytic reaction — 1 (0.1)
Change in glucose tolerance — 1 (0.1)
Changes in visual acuity — —
Total event 9 (0.8) 8 (0.7)
Values are present as event of side effect number.
INH: Isoniazid, RIF: Rifampin, PZA: Pyrazinamide, SM: Streptodefinitive termination of any 1 of the drugs due to
cutaneous reactions was determined in 4 patients
(0.3%). The drug most responsible for developing a
cutaneous reaction and severe cutaneous side
effects was SM. Other drugs were RIF and PZA.
Flu-like syndrome was observed in 3 cases, in 2 of
which RIF therapy was discontinued. The interval
between the onset of treatment and flu-like
syndrome was 11.6 days (7–21 days). Two patients
had drug fever and the final cessation of PZA was
necessary in 1 of them. There were 2 patients who
developed gluteal abscess due to SM. EMB was
terminated due to changes in visual activity in 1
patient. INH was discontinued due to peripheral
neuropathy in 1 patient, RIF was discontinued
in 2 distinct patients because of the occurrence
of hemolytic reaction and changes in glucose
tolerance.Discussion
The results of this study indicate that intolerance
of anti-TB standard therapy due to the side effects
of anti-TB drugs is still a serious problem in the
hospital-treated patients with tuberculosis. In our
study, we found that the current incidence of side
effects was 8.3%, in a total of 104 events. Although
the major severe side effects were ototoxicity,
hepatotoxicity, neuropsychiatric manifestations,
and hyperuricemia, the incidence of severe side
effects was not as high as in the other studies
(range 5.1–23%)4,7,8: total complication rate due to
anti-TB drugs were 57 events, with low life-
threatening complications.PZA, SM, EMB (57 events in 51 patients).
PZA n (%) SM n (%) EMB n (%) Total n (%)
7 (0.6) — — 9 (0.8)
— 19 (1.7) — 19 (1.7)
— — — 8 (0.7)
7 (0.6) — — 7 (0.6)
1 (0.1) 2 (0.2) — 4 (0.3)
2 (0.2) — — 2 (0.2)
— — — 3 (0.26)
— — — 1 (0.1)
— 1 (0.1) — 1 (0.1)
— — — 1 (0.1)
— — — 1 (0.1)
— — 1 (0.1) 1 (0.1)
17 (1.5) 22 (1.9) 1 (0.1) 57
mycin, EMB: Ethambutol.
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B.E. Gu¨lbay et al.1840The incidence rate of side effects other than
hepatotoxicity was especially low and in accor-
dance with published rates. However, hyperurice-
mia was found to be the most frequent side effect
caused by anti-TB drugs in the present study.
Although we observed elevated uric acid levels in
2.7% of our patients, this rate was 40–47% in
previously published 2 series.9,10 In another study,
while hyperuricemia was detected in 44 of 51
patients who were initiated PZA for tuberculosis;
non-gouty arthralgia was observed in only 9
patients.6 Also, it was accepted that the impor-
tance of arthralgia or drug-induced hyperuricemia
in the initial intensive phase of treatment was
controversial1,3; PZA was discontinued due to
persistent arthralgia with hyperuricemia in 7
(0.6%) patients in our study. Incidence of arthralgia
that resulted in the discontinuation of PZA similar
to that reported in other series (0.2%, 2%).3,7
Ototoxicity that manifested itself either as
auditory or vestibular damage was found to be
the most frequent severe side effect (1.7%) in the
present study. All patients with ototoxicity used SM
for at least 14 days and gender was not found to be
associated with ototoxicity as in the study of De
Jager and Van Altena,11 which investigated the
ototoxic and nephrotoxic effects of long-term use
of aminoglycosides for anti-TB therapy. None of the
patients had used loop-inhibiting diuretics asso-
ciated with an increased ototoxicity risk,1 and SM
was discontinued immediately after the develop-
ment of ototoxicity.
While asymptomatic liver function disturbance
was established in 56 patients (4.9%) on anti-TB
therapy, rate of hepatotoxicity was 2.4%. It is
important to note that an asymptomatic increase in
serum liver function tests occurs in nearly 20% of
the patients on anti-TB therapy and in the absence
of symptoms, treatment should not be altered.9
However, it must also be remembered that hepa-
totoxicity is an important side effect related to
anti-TB drugs. Hepatotoxicity causes significant
morbidity and mortality, and modification of the
drug regimen may be required.12 For this reason,
identification of patients associated with increased
risk for hepatotoxicity is necessary. It was deter-
mined that the incidence of hepatotoxicity varied
between 4.3% and 19% in published studies from
various countries.3,4,8,12–17 Despite the efforts
spent for defining the exact risk of developing
hepatotoxicity during anti-TB therapy, factors
predicting the development of hepatotoxicity are
still controversial. Besides, it is difficult to assess
the real incidence of hepatotoxicity in selected
patient groups from the published data, because
different definitions are used for hepatotoxicity.Reported risk factors for hepatotoxicity include old
age, female sex, history of hepatitis, high alcohol
intake, concomitant intake of other hepatotoxic
drugs, poor nutritional status, advanced disease,
pre-existing liver disease, and acetylator status in
literature.3,18–20
In contrast to multiple published stu-
dies,3,7,8,12,16,19,20 there was no increased risk of
hepatotoxicity among elderly patients in this
present study. On the other hand, there are some
similar studies in the literature, which have shown
that there is no relationship between the risk of
hepatotoxicity and age.13,15,21–23 We thought that it
could be associated with the average age, and low
number of patients X60 years compared to the
other study. Besides, the relationship between the
risk of developing hepatotoxicity and age in the
present study was similar to that reported in a
series with a total 786 of patients.13,15,21,22
In our study, although there was no equal
distribution of gender, we found that the risk of
hepatotoxicity was slightly higher in male patients,
but this was not significant. However, there were
some studies reporting a higher risk of hepatotoxi-
city in female patients,3,4,7,8,15,16,21,22,24,25 and
also, some other studies that show no differences
between the,two genders for the risk of developing
hepatotoxicity.12,19,21,23,26 two Similarly, radiologi-
cal extension and history of alcohol consumption
could not be suggested as risk factors for hepato-
toxicity in our study. These results may have been
limited by the small number of patients with
hepatitis B carriers and alcohol consumption.
When anti-TB therapy was discontinued, liver
function tests returned to normal in all of the 28
patients with hepatotoxicity. Anti-TB medications
were reintroduced one by one in gradually increas-
ing doses to 10 patients, and the same doses were
administered to the remaining 18 patients when-
ever liver functions returned to normal level.
Eleven patients developed recurrent hepatotoxicity
that required the cessation of 1 or more anti-TB
drugs due to severe hepatotoxicity in 9 of them.
Although Tahaoglu et al.5 showed that re-treatment
with a full-dose anti-TB regimen caused more
hepatotoxicity in their study, we did not have a
significant variation between the development risk
of severe and/or recurrent hepatotoxicity and 2
distinct retreatment protocols as in the study of
Sharma et al.12 The incidence of severe hepato-
toxicity related to the anti-TB drugs was 0.8% and
PZA most the frequently terminated drug for
hepatotoxicity in our study. Our results are in
agreement with those of 4 series3,4,7,8 and PZA was
the most frequent causative agent for hepatotoxi-
city in these studies too.
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was quite different from most previously published
studies (range 2.7–11%).3,7 There are some reasons
related to this rate; firstly, we thought that the low
number of patients with risk factors for hepato-
toxicity such as alcohol intake, i.v. drug abuse, or
concomitant use of other hepatotoxicity drugs, and
comorbid conditions like pre-existing liver diseases
and human immunodeficiency virus (HIV) infection,
could be effective in the low rate of severe
hepatotoxicity. Secondly, the patient groups did
not include young children who may imply totally
different risk factors. Interestingly, severe hepato-
toxicity was more frequent in younger patients and
male gender was also associated with increased
risk for severe hepatotoxicity in our study. A
similar occurrence rate of severe hepatotoxicity
in male patients was found as in the study of
Ohkawa et al.22
The rate of neuropsychiatric events related to
INH was 0.7% in our study. While Schaberg et al.3
found the rate of neuropsychiatric problems as 1.5%
in their study, it was higher (30–37%) in different
series that included specific risk groups such as
patients with chronic renal failure, multi drug
resistance TB.27,28 No high cutaneous adverse
reaction rates with anti-TB drugs were identified,
as reported in 3 other series (respectively; 6%, 6%,
30.4%, 4.8%).3,7,23,29 In our study, visual toxicity
due to EMB occurred in only 1 patient (0.1%) as
reported in the study of Yee et al. (0.2%).7
There are some parts that may be improved in
our retrospective study. The results obtained in this
study are clearly not representative of all tubercu-
losis patients, for instance, the outcomes of
outpatients are not included and the side effects
related to anti-TB drugs include only those that
evolved in the initial phase of anti-TB therapy, not
inclusive of the entire treatment duration. Another
limitation is that there were few patients with
extra-pulmonary disease in this study, thus limiting
interferences to this group of patients who might
tolerate therapy differently. Finally, there is the
issue of deficient patient records. Despite all, the
results of our hospital are valuable in order to
manage the treatment of patients with pulmonary
tuberculosis.
Management of active tuberculosis includes the
initiation and the completion of anti-TB therapy,
and also the interference of side effects related to
anti-TB drugs. In conclusion, it must be kept in
mind that severe side effects with anti-TB drugs are
common especially among patients hospitalized for
pulmonary tuberculosis and they should be fol-
lowed up by closer monitoring for the side effects
related to anti-TB drugs.References
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